Deepak Nath, the Chief Executive Officer of medical technology group Smith & Nephew (SN), is set to expand his professional portfolio. A regulatory filing confirmed on Tuesday that Nath will take on an additional role as an independent Non-Executive Director at Reckitt Benckiser Group, effective April 1, 2026.
A Strategic Appointment for 2026
The announcement, made
Nath will assume his new position in a non-executive capacity, meaning he will not hold an operational management role at Reckitt Benckiser. His primary executive duties and strategic leadership will remain firmly with Smith & Nephew.
Should investors sell immediately? Or is it worth buying Smith &ephewS?
Governance and Leadership Capacity in Focus
The assumption of external board mandates by sitting CEOs is typically monitored closely by investors. A key consideration is whether the added responsibility might impact the executive’s focus on their primary company’s day-to-day operations and strategic direction.
While the appointment underscores Nath’s standing and connectivity within the broader industry, it necessitates careful management of time and commitments. Beginning his tenure in April 2026, Nath will provide external oversight at Reckitt Benckiser while continuing to steer the operational and strategic helm at Smith & Nephew.
Ad
Smith &ephewS Stock: Buy or Sell?! New Smith &ephewS Analysis from April 17 delivers the answer:
The latest Smith &ephewS figures speak for themselves: Urgent action needed for Smith &ephewS investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 17.
Smith &ephewS: Buy or sell? Read more here...
